Page 2 - Rituximab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rituximab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rituximab Today - Breaking & Trending Today

Dr Castillo on Acalabrutinib Plus Rituximab in Patients With Anti-MAG IgM Peripheral Neuropathy

Jorge J. Castillo, MD, discusses preliminary data from a phase 2 study of acalabrutinib plus rituximab in patients with IgM symptomatic anti-MAG peripheral neuropathy. ....

Jorgej Castillo , Harvard Medical School , Dana Farber Cancer Institute , Bing Center , Onclive Tv , Hematologic Oncology , Mash 2023 , Waldenström Macroglobulinemia , Anti Mag , Peripheral Neuropathy ,

Current Treatment Options in First-Line MCL

Experts on mantle cell lymphoma discuss first-line treatment options available for patients. ....

Recent Updates , Follicular Lymphoma , Mantle Cell Lymphoma , Treatment Options , Btk Inhibitors , Indolent Biology , Intensive Therapy , Frontline Therapy , Consolidation Therapy , Autologous Stem Cell Transplant , Mcl Treatment , Mantle Cell Lymphoma Treatment ,

Long-Term, Sustained Remission of Pemphigus Observed in Patients Treated with Rituximab

These data were the results of the secondary analysis of the Ritux 3 study, as the treatment’s short-term efficacy and safety had been confirmed previously.
....

France General , Haute Normandie , Billal Tedbirt , Normandie University In Rouen , Normandie University , Dsg Abs , Long Term ,

EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab With Rituximab and Lenalidomide (R2) vs R2 Alone in Patients With Relapsed or Refractory Follicular Lymphoma

Lorenzo Falchi, MD, discusses the ongoing EPCORE FL-1 phase 3 trial investigating epcoritamab-rituximab-lenalidomide vs rituximab-lenalidomide in patients with relapsed or refractory follicular lymphoma. ....

United States , San Diego , Lorenzo Falchi , Drug Administration , Eastern Cooperative Oncology Group , Subcutaneous Epcoritamab With Rituximab , Patients With Relapsed , Refractory Follicular , Partnership With , North America , South America , Subcutaneous Epcoritamab , Epcore Fl 1 , Follicular Lymphoma , Relapsed Refractory Follicular Lymphoma , Epcore Fl 1 Trial , Relapsed Follicular Lymphoma , Refractory Follicular Lymphoma , Epcore Fl 1 Results , Epcore Fl 1 Data ,

Study Highlights Treatment Patterns, Costs for DLBCL Not Treated With Stem Cell Transplant

Most patients in the cohort received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for first-line therapy; hospitalization was prevalent; and average medical and pharmacy costs were more than $140,000 per patient per year. ....

International Classification Of Disease , International Prognostic Index , International Classification , Stem Cell Transplant , Treatment Patterns , Health Care Costs , R Chop ,